Results 21 to 30 of about 11,301 (165)
Revue medicale suisse, 2017 Observational data show a consistent association between elevated low density lipoproteins (LDL-C) and cardiovascular disease (CVD). Reduction of LDL-C reduces the risk of CVD as has been shown by many trials. Statins are currently the most effective drugs for lowering LDL-C, but can present side effects which might limit the prescribed dosage and ...
Petrova-Slater, Iveta +7 more
openaire +2 more sources
PCSK9 Inhibition: From Current Advances to Evolving Future
Cells, 2022 Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secretory serine protease synthesized primarily by the liver. It mainly promotes the degradation of low-density lipoprotein receptor (LDL-R) by binding LDL-R, reducing low-density lipoprotein ...
Chunping Liu +14 more
doaj +1 more source
PCSK9 inhibitor effectively alleviated cognitive dysfunction in a type 2 diabetes mellitus rat model [PDF]
PeerJBackground The incidence of diabetes-associated cognitive dysfunction (DACD) is increasing; however, few clinical intervention measures are available for the prevention and treatment of this disease.
Yang Yang +4 more
doaj +2 more sources
PCSK9 inhibitors and diabetes mellitus [PDF]
Vnitřní lékařství, 2018 Proproteinconvertase subtilisin kexin 9 (PCSK9) is a key regulator of low-density lipoprotein receptor (LDLR) expression. Anti-PCSK9 monoclonal antibody (MAb) therapy reduces LDL-cholesterol (LDL-C) by ~60 % and reduces also the risk of major adverse cardiovascular events.
Branislav, Vohnout +2 more
openaire +2 more sources
PCSK9 - new perspectives for lipid-lowering pharmacotherapy in patients with coronary artery disease [PDF]
Farmacja Polska, 2020 Optimal hypolipemic therapy reduces the risk of cardiovascular death. The drugs used in Poland are: statins, ion exchange resins, cholesterol absorption inhibitors, fibrates and proprotein subtylsin/cexin type 9 converting enzyme inhibitors (PCSK9).
Natalia Pauli, Monika Rac
doaj +1 more source
Frontiers in Pharmacology, 2022 Background: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are potent LDL-C lowering agents. However, few head-to-head studies evaluated the efficacy on the lowering in other atherogenic apolipoproteins and safety of PCSK9 ...
Yi-Ting Huang +9 more
doaj +1 more source
Safety, adherence and efficacy of PCSK9 inhibitors: a retrospective real-world study
Proceedings of Singapore Healthcare, 2022 Introduction PCSK9 inhibitors demonstrated their effectiveness in reducing low-density lipoprotein cholesterol (LDL-C) and cardiovascular events in landmark trials. It remains unclear whether the results can be translated to Asian populations. This study
Bee Ling Kelly Chng +6 more
doaj +1 more source
Adoption of PCSK9 Inhibitors Among Patients With Atherosclerotic Disease
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021 Background PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors represent a promising class of lipid‐lowering therapy, although their use has been limited by cost concerns.
Elias J. Dayoub +7 more
doaj +1 more source
PCSK9 peptide inhibitors [PDF]
Science-Business eXchange, 2014 Although many companies are chasing inhibitors of PCSK9 for lowering LDL cholesterol, antibodies or siRNAs that require injection are dominating the field. Roche's Genentech unit and a joint team from Pfizer and the University of Queensland are betting that peptides might provide an oral competitor.
openaire +1 more source
A Comprehensive Review of PCSK9 Inhibitors
Journal of Cardiovascular Pharmacology and Therapeutics, 2022 Cardiovascular disease (CVD) is the leading cause of death in the United States and worldwide. A major risk factor for this condition is increased serum low-density lipoprotein cholesterol (LDL-C) levels for which statins have been successful in reducing serum LDL-C to healthy concentrations. However, patients who are statin intolerant or those who do
Caroline Coppinger +5 more
openaire +3 more sources